Treatment Information

Back

Liver Cancer treatment details. Biologic therapy.

Chiba University Hospital, Chiba, Japan.

Survival: monthsCountry:Japan
Toxiciy Grade:4City/State/Province:Chiba
Treatments:Biologic therapyHospital:Chiba University Hospital
Drugs:Journal:Link
Date:Feb 2011

Description:

Patients:
This study involved 35 patients with advanced hepatocellular carcinoma. The median age of the group was 68 years and 29 were male.

Treatment:
Patients were treated with the biologic therapy called TSU-68, which is a tyrosine kinase inhibitor.

Toxicities:
Maximum toxicity grade was 4, including 1 case of decreased hemoglobin. Grade 3 diarrhea, abdominal pain, and anorexia were also reported.

Results:
The reported median overall survival was 13.1 months.

Support:
This study was supported by Taiho Pharmaceuticals, makers of TSU-68.

Correspondence: Dr. Fumihiko Kanai; email: [email protected]



Back